1 INDICATIONS AND USAGE
Valacyclovir tablet is a deoxynucleoside analogue DNA polymerase inhibitor indicated for:
Adult Patients (1.1)
Cold Sores (Herpes Labialis)
Genital Herpes
Treatment in immunocompetent patients (initial or recurrent episode)
Suppression in immunocompetent or HIV-1infected patients
Reduction of transmission
Herpes Zoster
Pediatric Patients (1.2)
Cold Sores (Herpes Labialis)
Chickenpox
Limitations of Use (1.3)
The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the
suppression of genital herpes in HIV-1infected patients.
1.1 Adult patients
Cold Sores (Herpes Labialis)
Valacyclovir tablets are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets initiated after
the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.
Genital Herpes
Initial Episode: Valacyclovir tablets are indicated for treatment of the initial episode of genital herpes in immunocompetent
adults. The efficacy of treatment with valacyclovir tablets when initiated more than 72 hours after the onset of signs and
symptoms has not been established.
Recurrent Episodes: Valacyclovir tablets are indicated for treatment of recurrent episodes of genital herpes in
immunocompetent adults. The efficacy of treatment with valacyclovir tablets when initiated more than 24 hours after the
onset of signs and symptoms has not been established.
Suppressive Therapy: Valacyclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of genital
herpes in immunocompetent and in HIV-1infected adults. The efficacy and safety of valacyclovir tablets for the suppression
of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-1infected patients have not been
established.
Reduction of Transmission: Valacyclovir tablets are indicated for the reduction of transmission of genital herpes in
immunocompetent adults. The efficacy of valacyclovir tablets for the reduction of transmission of genital herpes beyond 8
months in discordant couples has not been established. The efficacy of valacyclovir tablets for the reduction of transmission
of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex
practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC]
Sexually
Transmitted Diseases Treatment Guidelines).
Herpes Zoster
Valacyclovir tablets are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of
valacyclovir tablets when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir
tablets for treatment of disseminated herpes zoster have not been established.
1.2 Pediatric Patients
Cold Sores (Herpes Labialis)
Valacyclovir tablets are indicated for the treatment of cold sores (herpes labialis) in pediatric patients aged greater than or
equal to 12 years. The efficacy of valacyclovir tablets initiated after the development of clinical signs of a cold sore (e.g.,
papule, vesicle, or ulcer) has not been established.
Chickenpox
Valacyclovir tablets are indicated for the treatment of chickenpox in immunocompetent pediatric patients aged 2 to less than
18 years. Based on efficacy data from clinical trials with oral acyclovir, treatment with valacyclovir tablets should be initiated
within 24 hours after the onset of rash
[see Clinical Studies (14.4)].
1.3 Limitations of Use
The efficacy and safety of valacyclovir tablets have not been established in:
Immunocompromised patients other than for the suppression of genital herpes in HIV-1infected patients with a CD4+
cell count greater than or equal to 100 cells/mm3.
Patients aged less than 12 years with cold sores (herpes labialis).
Patients aged less than 2 years or greater than or equal to 18 years with chickenpox.
Patients aged less than 18 years with genital herpes.
Patients aged less than 18 years with herpes zoster.
Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.